Molecular Imaging Probes for Diagnosis and Therapy Evaluation of Breast Cancer
暂无分享,去创建一个
[1] John B. Shoven,et al. I , Edinburgh Medical and Surgical Journal.
[2] G. G. Stokes. "J." , 1890, The New Yale Book of Quotations.
[3] D. Lipman,et al. National Center for Biotechnology Information , 2019, Springer Reference Medizin.
[4] M J Welch,et al. Assessment of 21-[18F]fluoro-16 alpha-ethyl-19-norprogesterone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[5] W Vaalburg,et al. Preclinical evaluation of a positron emitting progestin ([18F]fluoro-16 alpha-methyl-19-norprogesterone) for imaging progesterone receptor positive tumours with positron emission tomography. , 1991, Cancer letters.
[6] David J. Yang,et al. Imaging, biodistribution and therapy potential of halogenated tamoxifen analogues. , 1994, Life sciences.
[7] H. Werner,et al. The Role of the Insulin‐like Growth Factor‐I Receptor in Cancer , 1995, Annals of the New York Academy of Sciences.
[8] A. Buzdar,et al. Positron emission tomography using [18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study. , 1996, Cancer biotherapy & radiopharmaceuticals.
[9] Michael G. Stabin,et al. Biodistribution and dosimetry of iodine-123-labelled Z-MIVE: an oestrogen receptor radioligand for breast cancer imaging , 1997, European Journal of Nuclear Medicine.
[10] P. Nielsen,et al. Progress in developing PNA as a gene-targeted drug. , 1997, Antisense & nucleic acid drug development.
[11] E. Endert,et al. The Z-isomer of 11β-methoxy-17α-[123I]iodovinylestradiol is a promising radioligand for estrogen receptor imaging in human breast cancer☆ , 1997 .
[12] B. Nordén,et al. Peptide nucleic acid (PNA): its medical and biotechnical applications and promise for the future , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[13] A. Ullrich,et al. HER2/neu: a target for breast cancer therapy. , 2000, Breast disease.
[14] A. Shields,et al. Radiosynthesis of 3'-deoxy-3'-[(18)F]fluorothymidine: [(18)F]FLT for imaging of cellular proliferation in vivo. , 2000, Nuclear medicine and biology.
[15] S. Achilefu,et al. Novel fluorescent contrast agents for optical imaging of in vivo tumors based on a receptor-targeted dye-peptide conjugate platform. , 2001, Journal of biomedical optics.
[16] P. Beuzeboc,et al. Targeting HER2 in other tumor types. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] W. Semmler,et al. Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands , 2001, Nature Biotechnology.
[18] L. Wiens,et al. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[19] Yann Seimbille,et al. 18F-labeled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals , 2002, Steroids.
[20] Janet E Dancey. Recent advances of molecular targeted agents: opportunities for imaging. , 2003, Cancer biology & therapy.
[21] Ignasi Carrió,et al. European Journal of Nuclear Medicine and Molecular Imaging manuscript processing goes online , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[22] A. ADoefaa,et al. ? ? ? ? f ? ? ? ? ? , 2003 .
[23] Chun Li,et al. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. , 2003, Cancer research.
[24] Janet Dancey. Recent Advances with Molecular Target Agents in Cancer: Opportunities for Imaging , 2003 .
[25] Neal Rosen,et al. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors , 2004, Nature Biotechnology.
[26] Gerald Reischl,et al. PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[27] Ryan Park,et al. MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. , 2004, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.
[28] J. Soria,et al. Molecular targeting: targeting angiogenesis in solid tumors. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] Ryan Park,et al. MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. , 2004, Bioconjugate chemistry.
[30] Mark Muzi,et al. 18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[31] Eric Wickstrom,et al. External imaging of CCND1 cancer gene activity in experimental human breast cancer xenografts with 99mTc-peptide-peptide nucleic acid-peptide chimeras. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[32] Emily White,et al. Factors contributing to mammography failure in women aged 40-49 years. , 2004, Journal of the National Cancer Institute.
[33] P. Chevallier,et al. Overexpression of Her2/neu is observed in one third of adult acute lymphoblastic leukemia patients and is associated with chemoresistance in these patients. , 2004, Haematologica.
[34] Michael J. Welch,et al. Synthesis of an Estrogen Receptor β-Selective Radioligand: 5-[18F]Fluoro-(2R*,3S*)-2,3-bis(4-hydroxyphenyl)pentanenitrile and Comparison of in Vivo Distribution with 16α-[18F]Fluoro-17β-estradiol , 2005 .
[35] Eric Wickstrom,et al. Noninvasive molecular imaging of MYC mRNA expression in human breast cancer xenografts with a [99mTc]peptide-peptide nucleic acid-peptide chimera. , 2005, Bioconjugate chemistry.
[36] François Bénard,et al. Imaging in breast cancer: Single-photon computed tomography and positron-emission tomography , 2005, Breast Cancer Research.
[37] Maria Sjöberg,et al. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. , 2005, Molecular endocrinology.
[38] Kaijun Zhang,et al. External Imaging of CCND1, MYC, and KRAS Oncogene mRNAs with Tumor‐Targeted Radionuclide‐PNA‐Peptide Chimeras , 2005, Annals of the New York Academy of Sciences.
[39] A. Fangberget,et al. Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[40] Weibo Cai,et al. A thiol-reactive 18F-labeling agent, N-[2-(4-18F-fluorobenzamido)ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of alpha v beta 3 integrin expression. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[41] A. Citri,et al. EGF–ERBB signalling: towards the systems level , 2006, Nature Reviews Molecular Cell Biology.
[42] Neil Genzlinger. A. and Q , 2006 .
[43] Weibo Cai,et al. A Thiol-Reactive 18F-Labeling Agent, N-[2-(4-18F-Fluorobenzamido)Ethyl]Maleimide, and Synthesis of RGD Peptide-Based Tracer for PET Imaging of αvβ3 Integrin Expression , 2006 .
[44] Dong Wook Kim,et al. Fluorine-substituted cyclofenil derivatives as estrogen receptor ligands: synthesis and structure-affinity relationship study of potential positron emission tomography agents for imaging estrogen receptors in breast cancer. , 2006, Journal of medicinal chemistry.
[45] David J. Yang,et al. Targeted functional imaging of estrogen receptors with 99mTc-GAP-EDL , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[46] Funda Meric-Bernstam,et al. Advances in Targeting Human Epidermal Growth Factor Receptor-2 Signaling for Cancer Therapy , 2006, Clinical Cancer Research.
[47] Ludovic Ferrer,et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] D. Mankoff,et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] A. Dueñas-González,et al. Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. , 2006, Cancer treatment reviews.
[50] M L Thakur,et al. Receptor-mediated internalization of chelator-PNA-peptide hybridization probes for radioimaging or magnetic resonance imaging of oncogene mRNAs in tumours. , 2007, Biochemical Society transactions.
[51] Xiaoyuan Chen,et al. Preparation and characterization of 99mTc(CO)3–BPy–RGD complex as αvβ3 integrin receptor-targeted imaging agent , 2007 .
[52] Michael J Welch,et al. Synthesis and biodistribution of fluorine-18-labeled fluorocyclofenils for imaging the estrogen receptor. , 2007, Nuclear medicine and biology.
[53] Konstantin V Balakin,et al. VEGF/VEGFR signalling as a target for inhibiting angiogenesis , 2007, Expert opinion on investigational drugs.
[54] Amir Kashefi,et al. A new PET tracer specific for vascular endothelial growth factor receptor 2 , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[55] Heinrich R Schelbert,et al. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[56] Kaijun Zhang,et al. PET Imaging of CCND1 mRNA in Human MCF7 Estrogen Receptor–Positive Breast Cancer Xenografts with Oncogene-Specific [64Cu]Chelator-Peptide Nucleic Acid-IGF1 Analog Radiohybridization Probes , 2007, Journal of Nuclear Medicine.
[57] Young-Seung Kim,et al. Evaluation of a 99mTc-Labeled Cyclic RGD Tetramer for Noninvasive Imaging Integrin αvβ3-Positive Breast Cancer , 2007 .
[58] John C Gore,et al. Molecular Imaging of Vascular Endothelial Growth Factor Receptor 2 Expression Using Targeted Contrast‐Enhanced High‐Frequency Ultrasonography , 2007, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.
[59] David Milstein,et al. Water-soluble contrast agents targeted at the estrogen receptor for molecular magnetic resonance imaging. , 2007, Bioconjugate chemistry.
[60] Jinming Yu,et al. Assessment of 11C‐labeled‐4‐N‐(3‐bromoanilino)‐6, 7‐dimethoxyquinazoline as a positron emission tomography agent to monitor epidermal growth factor receptor expression , 2007, Cancer science.
[61] Eric R. Prossnitz,et al. Preclinical Development of a Neutral, Estrogen Receptor–Targeted, Tridentate 99mTc(I)-Estradiol-Pyridin-2-yl Hydrazine Derivative for Imaging of Breast and Endometrial Cancers , 2008, Journal of Nuclear Medicine.
[62] G. Liu,et al. Targeted Herceptin–dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI , 2009, JBIC Journal of Biological Inorganic Chemistry.
[63] Bart Cornelissen,et al. Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[64] Kemin Wang,et al. Imaging breast cancer cells and tissues using peptide-labeled fluorescent silica nanoparticles. , 2008, Journal of nanoscience and nanotechnology.
[65] Min Wang,et al. Synthesis and preliminary biological evaluation of new carbon-11 labeled tetrahydroisoquinoline derivatives as SERM radioligands for PET imaging of ER expression in breast cancer. , 2008, European journal of medicinal chemistry.
[66] Nadia Harbeck,et al. Patterns of αvβ3 Expression in Primary and Metastatic Human Breast Cancer as Shown by 18F-Galacto-RGD PET , 2008, Journal of Nuclear Medicine.
[67] A. Zytoon,et al. Dual time point FDG-PET/CT imaging... Potential tool for diagnosis of breast cancer. , 2008, Clinical radiology.
[68] Vladimir Tolmachev,et al. Disruption of HER2 signalling by the monoclonal antibody trastuzumab or the tyrosine kinase inhibitor lapatinib improves survival of patients with metastatic breast , 2010 .
[69] S. Shousha,et al. Altered Tissue 3′-Deoxy-3′-[18F]Fluorothymidine Pharmacokinetics in Human Breast Cancer following Capecitabine Treatment Detected by Positron Emission Tomography , 2009, Clinical Cancer Research.
[70] Jean-Mathieu Beauregard,et al. Assessment of Human Biodistribution and Dosimetry of 4-Fluoro-11β-Methoxy-16α-18F-Fluoroestradiol Using Serial Whole-Body PET/CT , 2008, Journal of Nuclear Medicine.
[71] Bart Cornelissen,et al. Micro-SPECT/CT with 111In-DTPA-Pertuzumab Sensitively Detects Trastuzumab-Mediated HER2 Downregulation and Tumor Response in Athymic Mice Bearing MDA-MB-361 Human Breast Cancer Xenografts , 2009, Journal of Nuclear Medicine.
[72] Winfried Brenner,et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] Jurgen Seidel,et al. Dual-modality molecular imaging using antibodies labeled with activatable fluorescence and a radionuclide for specific and quantitative targeted cancer detection. , 2009, Bioconjugate chemistry.
[74] Johan R de Jong,et al. Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging , 2009, Journal of Nuclear Medicine.
[75] Christine Desmedt,et al. HER-2 as a Target for Breast Cancer Therapy , 2009, Clinical Cancer Research.
[76] Joachim Feldwisch,et al. Targeting of HER2-Expressing Tumors with a Site-Specifically 99mTc-Labeled Recombinant Affibody Molecule, ZHER2:2395, with C-Terminally Engineered Cysteine , 2009, Journal of Nuclear Medicine.
[77] Jacek Capala,et al. Changes in HER2 Expression in Breast Cancer Xenografts After Therapy Can Be Quantified Using PET and 18F-Labeled Affibody Molecules , 2009, Journal of Nuclear Medicine.
[78] Hamidreza Ghandehari,et al. Noninvasive Monitoring of HPMA Copolymer–RGDfK Conjugates by Magnetic Resonance Imaging , 2009, Pharmaceutical Research.
[79] Xu Hun,et al. Anti-epidermal growth factor receptor (anti-EGFR) antibody conjugated fluorescent nanoparticles probe for breast cancer imaging. , 2009, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
[80] D. Yee,et al. Fluorescent tumour imaging of type I IGF receptor in vivo: comparison of antibody-conjugated quantum dots and small-molecule fluorophore , 2009, British Journal of Cancer.
[81] E. D. de Vries,et al. Molecular imaging of breast cancer. , 2009, Breast.
[82] Perihan Unak,et al. Synthesis of a novel antiestrogen radioligand (99mTc-TOR-DTPA). , 2009, Cancer biotherapy & radiopharmaceuticals.
[83] B. McParland,et al. An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the αv β 3-selective angiogenesis imaging agent 99mtc-nc100692 , 2010, Acta radiologica.
[84] Naoya Hashimoto,et al. MR molecular imaging of HER-2 in a murine tumor xenograft by SPIO labeling of anti-HER-2 affibody. , 2010, Contrast media & molecular imaging.
[85] Fredrik Y Frejd,et al. Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications , 2010, FEBS letters.
[86] E. Rutgers,et al. The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[87] M. Campiglio,et al. HER2 as a target for breast cancer therapy , 2010, Expert opinion on biological therapy.
[88] Joachim Feldwisch,et al. Design of an optimized scaffold for affibody molecules. , 2010, Journal of molecular biology.
[89] Michael Rugaard Jensen,et al. (89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. , 2010, European journal of cancer.
[90] Christopher G Mayne,et al. Imaging progesterone receptor in breast tumors: synthesis and receptor binding affinity of fluoroalkyl-substituted analogues of tanaproget. , 2010, Journal of medicinal chemistry.
[91] W. Oyen,et al. ImmunoSPECT and ImmunoPET of IGF-1R Expression with the Radiolabeled Antibody R1507 in a Triple-Negative Breast Cancer Model , 2010, The Journal of Nuclear Medicine.
[92] Deepa Narayanan,et al. Positron emission mammography in breast cancer presurgical planning: comparisons with magnetic resonance imaging , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[93] P. L. Jager,et al. Biodistribution of 89Zr‐trastuzumab and PET Imaging of HER2‐Positive Lesions in Patients With Metastatic Breast Cancer , 2010, Clinical pharmacology and therapeutics.
[94] J. Capala,et al. Molecular imaging of HER2-positive breast cancer: a step toward an individualized ‘image and treat’ strategy , 2010, Current opinion in oncology.
[95] Carl V Hamby,et al. Molecular Imaging of Changes in the Prevalence of Vascular Endothelial Growth Factor Receptor in Sunitinib-Treated Murine Mammary Tumors , 2010, Journal of Nuclear Medicine.
[96] Michael J Welch,et al. Development of [F-18]fluorine-substituted Tanaproget as a progesterone receptor imaging agent for positron emission tomography. , 2010, Bioconjugate chemistry.
[97] Chan Woo Park,et al. HER2/neu antibody conjugated poly(amino acid)-coated iron oxide nanoparticles for breast cancer MR imaging. , 2010, Biomacromolecules.
[98] Kyung-Han Lee,et al. 99mTc-Hydrazinonicotinamide Epidermal Growth Factor–Polyethylene Glycol–Quantum Dot Imaging Allows Quantification of Breast Cancer Epidermal Growth Factor Receptor Expression and Monitors Receptor Downregulation in Response to Cetuximab Therapy , 2011, The Journal of Nuclear Medicine.
[99] Federico Turkheimer,et al. [18F]-3′Deoxy-3′-Fluorothymidine Positron Emission Tomography and Breast Cancer Response to Docetaxel , 2011, Clinical Cancer Research.
[100] Wolfhard Semmler,et al. A novel PET tracer for the imaging of αvβ3 and αvβ5 integrins in experimental breast cancer bone metastases. , 2011, Contrast media & molecular imaging.
[101] Kishore Bhakoo,et al. Molecular Targeting of Breast Cancer: Molecular Imaging and Therapy , 2011 .
[102] Woo Kyung Moon,et al. Comparison of diffusion-weighted MR imaging and FDG PET/CT to predict pathological complete response to neoadjuvant chemotherapy in patients with breast cancer , 2011, European Radiology.
[103] Otto C. Boerman,et al. PP 46 In vivo imaging of modulation of IGF-1R expression in breast cancer models , 2011 .
[104] Ramasamy Paulmurugan,et al. Imaging cellular receptors in breast cancers: an overview. , 2011, Current pharmaceutical biotechnology.
[105] Nick Devoogdt,et al. Preclinical screening of anti‐HER2 nanobodies for molecular imaging of breast cancer , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[106] Kumar Sharma,et al. Ultrasound Molecular Imaging of Tumor Angiogenesis With an Integrin Targeted Microbubble Contrast Agent , 2011, Investigative radiology.
[107] Sanjiv S Gambhir,et al. Optical Imaging with Her2-Targeted Affibody Molecules Can Monitor Hsp90 Treatment Response in a Breast Cancer Xenograft Mouse Model , 2012, Clinical Cancer Research.
[108] Zhen Cheng,et al. Evaluation of four affibody-based near-infrared fluorescent probes for optical imaging of epidermal growth factor receptor positive tumors. , 2011, Bioconjugate chemistry.
[109] J. Benlloch,et al. Molecular Imaging in Breast Cancer , 2012, Journal of oncology.
[110] W. Marsden. I and J , 2012 .
[111] G. Antoch,et al. Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[112] David J. Yang,et al. Targeted nuclear imaging of breast cancer: status of radiotracer development and clinical applications. , 2012, Cancer biotherapy & radiopharmaceuticals.
[113] Macarena Rodríguez-Fraile,et al. PET Tracers for Clinical Imaging of Breast Cancer , 2012, Journal of oncology.